Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin

Overview of attention for article published in Investigational New Drugs, September 2012

Altmetric Badge

Mentioned by

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 76,725 followers.

マイロターグという抗癌剤の承認に関して、世界の規制当局の差を検証しました。これについては日本のPMDAは良い仕事をしています。谷本哲也と坪倉正治の仕事です。 http://t.co/oxBF2tb2

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.